Q&A

Executive Q&A: Robert C. Coborn, CEO, MicroBioLogics, Inc.

Source: MicroBioLogics, Inc.
In this article, we ask Coborn about the biggest challenges facing today's pharmaceutical quality control laboratories, why these laboratories should consider stock microorganisms over in-house preparations, and what the future might hold for the pharmaceutical and bioresearch industries.

access the Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

Please tell us more about you so that we can customize our newsletters to your specific interests: